This study investigates the effectiveness of an investigational medication following combined modality therapy in treating patients with high risk stage II-IIIB anal cancer. Anal cancer is a disease where malignant cells form in the tissues of the anus. The investigational medication is being studied to see if it can improve disease-free survival, which means the length of time after treatment during which no cancer is found, compared to just observing the patient without further treatment.
Participants in this study will receive combined modality therapy, which is a treatment that combines more than one method, such as chemotherapy and radiation. Afterward, they will receive either the investigational medication or be placed under observation to compare outcomes. The investigational medication is not yet approved for this use and is being tested to see how well it works.
- Who can participate: Adults with stage II (T3N0 only), IIIA, or IIIB invasive anal squamous cell carcinoma can participate. Tumors may include non-keratinizing histology such as basaloid, transitional cell, or cloacogenic types. Patients with T1, T2N0, or M1 cancer are not eligible.
- Study details: Participants will undergo combined modality therapy, which includes treatments like chemotherapy and radiation. After this, they will either receive an investigational medication or be observed to compare the outcomes. The use of a placebo is not mentioned in the study details.
